Literature DB >> 12499217

Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains.

J M Loeffler1, V A Fischetti.   

Abstract

Pal and Cpl-1, two purified bacteriophage lytic enzymes, were tested for their in vitro activity, alone and in combination, against several serotypes of Streptococcus pneumoniae, including penicillin-resistant strains. The enzymes demonstrated synergism in their ability to cleave the bacterial peptidoglycan and thus may be more efficient for the prevention and elimination of pneumococcal colonization.

Entities:  

Mesh：

Year:  2003        PMID： 12499217      PMCID： PMC149014          DOI： 10.1128/AAC.47.1.375-377.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal.

Authors:  R Sá-Leão; A Tomasz; I S Sanches; A Brito-Avô; S E Vilhelmsson; K G Kristinsson; H de Lencastre
Journal:  J Infect Dis       Date:  2000-09-01       Impact factor: 5.226

2.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

Review 3.  Bacteriophages of Streptococcus pneumoniae: a molecular approach.

Authors:  P García; A C Martín; R López
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

Review 4.  Acute otitis media in the era of effective pneumococcal conjugate vaccine: will new pathogens emerge?

Authors:  S I Pelton
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

5.  The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin.

Authors:  M M Sheehan; J L García; R López; P García
Journal:  Mol Microbiol       Date:  1997-08       Impact factor: 3.501

6.  Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.

Authors:  J M Loeffler; D Nelson; V A Fischetti
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

7.  The impact of conjugate vaccine on carriage of Haemophilus influenzae type b.

Authors:  M L Barbour; R T Mayon-White; C Coles; D W Crook; E R Moxon
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226
  7 in total
  48 in total

1.  Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.

Authors:  Mathias Schmelcher; Anne M Powell; Stephen C Becker; Mary J Camp; David M Donovan
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

2.  Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance.

Authors:  Svetolik Djurkovic; Jutta M Loeffler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus.

Authors:  S O'Flaherty; A Coffey; W Meaney; G F Fitzgerald; R P Ross
Journal:  J Bacteriol       Date:  2005-10       Impact factor: 3.490

4.  Pneumococcal HtrA protease mediates inhibition of competence by the CiaRH two-component signaling system.

Authors:  M E Sebert; K P Patel; M Plotnick; J N Weiser
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

5.  Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1.

Authors:  Mourad Sabri; Roman Häuser; Marc Ouellette; Jing Liu; Mohammed Dehbi; Greg Moeck; Ernesto García; Björn Titz; Peter Uetz; Sylvain Moineau
Journal:  J Bacteriol       Date:  2010-11-19       Impact factor: 3.490

Review 6.  Recombinant bacteriophage lysins as antibacterials.

Authors:  Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

7.  Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.

Authors:  Wan Beom Park; Hong Bin Kim; Nak-Hyun Kim; Jeong Eun Cho; Yoon Jeong Choi; Su Jin Choi; Soo Youn Jun; Chang Kyung Kang; Kyoung-Ho Song; Pyoeng Gyun Choe; Ji-Hwan Bang; Eu Suk Kim; Sang Won Park; Nam-Joong Kim; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 8.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

9.  ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain.

Authors:  Hang Yang; Yujing Gong; Huaidong Zhang; Irina Etobayeva; Paulina Miernikiewicz; Dehua Luo; Xiaohong Li; Xiaoxu Zhang; Krystyna Dąbrowska; Daniel C Nelson; Jin He; Hongping Wei
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 10.  Bacteriophage lysins as effective antibacterials.

Authors:  Vincent A Fischetti
Journal:  Curr Opin Microbiol       Date:  2008-10-14       Impact factor: 7.934
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.